Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 15;7(4):1695-701.
eCollection 2014.

SKIP expression is correlated with clinical prognosis in patients with bladder cancer

Longwang Wang  1 , Mei Zhang  2 , Yong Wu  1 , Cheng Cheng  1 , Yawei Huang  1 , Zimin Shi  1 , Hongwei Huang  1
Affiliations

SKIP expression is correlated with clinical prognosis in patients with bladder cancer

Longwang Wang et al. Int J Clin Exp Pathol. .

Abstract

The Ski-interacting protein (SKIP) is a transcriptional cofactor distinct from other cofactors and is involved in regulation of many cancer-related proteins. However, its distribution and clinical significances in bladder cancer remains poorly understood. In this study, Quantitative real-time PCR and immunohistochemistry were performed to detect the expression of SKIP in clinical bladder cancer samples. In addition, the correlation of SKIP expression and clinicopathological features and clinical outcomes were analyzed. The expression levels of SKIP in clinical bladder cancer were much higher than that in paired adjacent noncancerous tissues. High expression of SKIP was closely related with histological grades and the poor prognosis of bladder cancer. Based on our data, we speculated that SKIP may be a potential prognostic marker in bladder cancer.

Keywords: SKIP expression; bladder cancer; prognosis.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Representative immunostaining of SKIP in high-grade urothelial carcinoma samples (A, B), and low-grade urothelial carcinoma samples (C, D). High expression of SKIP (A, B) is showed in high-grade urothelial carcinoma samples and low expression of SKIP (C, D) is showed in low-grade urothelial carcinoma samples.
Figure 1
Figure 1
Patients were divided into two groups: high SKIP expressers (n=51) and low SKIP expressers (n=19). Kaplan-Meier analysis of overall survival (A) and recurrence-free survival (B) in relation to skip expression in 70 bladder cancer patients showed a highly significant separation between curves.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13:310. - PMC - PubMed
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–465. discussion 475-467. - PubMed
    1. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155:1233–1238. - PubMed
    1. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol. 2010;58:486–494. - PubMed

MeSH terms

LinkOut - more resources